ClinicalTrials.gg
CompletedNCT07672977Nana-HomeUpdated Nov 13, 2026

Home-Based Closed-Loop Auditory Stimulation to Enhance Slow-Wave Activity in MCI Due to Alzheimer's Disease: A Proof-of-Concept Study

An interventional study of Closed-Loop Auditory Stimulation in MCI-AD, Early Stage Alzheimer's Disease, Alzheimer s Disease and Mild Cognitive Impairment (MCI) Amnestic, sponsored by Bitbrain. Completed at 1 site in Spain. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Bitbrain · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jul 2025, registered Jun 2026).
Updated Nov 13, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Cognitive Dysfunction with a site in Spain — 44 open to participants now, 61 under way, 9 of them phase 3. Cognitive Dysfunction · Spain.

Enrollment
117th of 127
25 · median 100
Started
2025
with 15 others
No phase
91 of 162
27 open now
Registered
158th of 162
by date
Lead sponsor
3 of 162
Bitbrain

Among the 162 studies in Cognitive Dysfunction with a site in Spain, this one is the 117th largest by enrollment of the 127 interventional ones that give a count, is one of 16 that started in 2025, is one of 91 with no phase, and was the 158th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

44 of the 162 studies in Cognitive Dysfunction with a site in Spain are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Cognitive Dysfunction with a site in Spain, or all of them as a file.
02

Study summary

This proof-of-concept study explores whether long-term home-based closed-loop auditory stimulation during sleep enhances slow-wave activity (SWA) and yields preliminary efficacy signals in patients with amnestic mild cognitive impairment due to Alzheimer's disease (MCI-AD), confirmed by cerebrospinal fluid (CSF) biomarkers or positron emission tomography (PET).

The intervention is self-administered at participants' homes over an initial treatment period of 3 months, followed by a 1-month off-treatment (washout) period. Participants may then enter an optional extension phase consisting of 3 additional months of treatment followed by a second 1-month washout period, for a total study duration of up to 8 months.

Participants who complete the Nana-Lab Study (NCT07402590) may be invited to provide informed consent for screening and potential enrollment in this study. All enrolled participants receive nightly active treatment during intervention periods. This study does not include randomization or a sham control group.

Read the detailed description

Alzheimer's disease (AD) is characterized by progressive cognitive decline and is preceded by a prodromal stage known as amnestic mild cognitive impairment due to AD (MCI-AD), in which early neurophysiological alterations are detectable. Among these, disruptions in sleep architecture-particularly reductions in slow-wave activity (SWA; \~0.5-4 Hz) and sleep spindle activity (\~11-16 Hz)-have been associated with impaired memory consolidation and the progression of AD-related pathophysiological processes.

Closed-loop auditory stimulation during sleep (CLAS) is a non-invasive neuromodulation approach that delivers precisely timed auditory stimuli phase-locked to endogenous slow oscillations, with the aim of enhancing slow-wave activity and associated thalamocortical spindle dynamics. This targeted entrainment of sleep oscillations may improve sleep-dependent neural processes and represents a potential therapeutic strategy in the early stages of AD.

The present study is an open-label, single-arm investigation designed to evaluate the effects of home-based CLAS in patients with biomarker-confirmed amnestic mild cognitive impairment due to Alzheimer's disease (MCI-AD). The intervention is self-administered in the participants' home environment. All participants complete an initial treatment period of 3 months followed by a one-month off-treatment (washout) period to assess persistence of effects. Participants who elect to continue may then enter an optional extension phase consisting of 3 additional months of treatment, followed by a second one-month off-treatment period. The total study duration is approximately 4 months for participants completing the initial phase only, or approximately 8 months for those completing the extension phase.

The primary objective is to assess target engagement, defined as the modulation of NREM sleep electrophysiological activity, with particular focus on slow-wave sleep. More precisely, sustained increases in slow-wave activity across the intervention period will be quantified using the study EEG device during intervention nights.

Secondary objectives include evaluation of adherence to the intervention, usability of the device in the home environment, and safety and tolerability. Exploratory objectives include evaluation of the intervention's effects on clinical, functional, cognitive, and sleep-related outcomes, as well as blood-based biomarkers. Clinical, functional, and cognitive variables will be assessed at three time points: before intervention (baseline, Month 0), at the end of the initial treatment period (Month 3), and, for participants entering the extension phase, at the end of the extended treatment period (Month 7).

Blood biomarkers will be obtained at the following time points: baseline (Month 0), end of the initial treatment period (Month 3), and end of the first washout period (Month 4). Participants entering the extension phase will have two additional blood draws: at the end of the extended treatment period (Month 7) and at the end of the second washout period (Month 8). Sleep metrics, derived from EEG recordings or subjective responses to digitized questionnaires, will be acquired daily using the home-based study device.

This study does not include randomization or a sham control group; all participants receive active treatment during intervention periods. The results are expected to provide evidence on neurophysiological target engagement, feasibility, safety, and the clinical and biological effects of home-based CLAS as a therapeutic strategy in early-stage AD.

03

Conditions studied

  • MCI-AD, Early Stage Alzheimer's Disease
  • Alzheimer s Disease
  • Mild Cognitive Impairment (MCI) Amnestic
  • AD
  • AD-MCI

Keywords

  • closed-loop auditory stimulation
  • sleep
  • wearable EEG
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 50 and 75 years (inclusive).
  • Spanish as native language.
  • Diagnosis of amnestic mild cognitive impairment due to Alzheimer's disease, confirmed by cerebrospinal fluid biomarkers or amyloid PET.
  • Normal or corrected-to-normal color vision (required for completion of visual-analog study assessments).
  • Adequate hearing to perceive the auditory stimuli used in the intervention, defined as a hearing threshold of 50 dB or below, assessed during the screening session.

Exclusion criteria

Exclusion criteria:

  • Severe systemic or complex chronic disease that, in the investigator's judgment, would compromise participant safety or data quality, including but not limited to: advanced heart disease; advanced chronic kidney disease (stage 4 or 5); severe pulmonary disease (e.g., GOLD stage III-IV); or terminal cancer; severe hematological disorders; or active or uncontrolled chronic infectious disease (e.g., untreated ).
  • Evidence on neuroimaging of strategic infarcts or other findings that may account for secondary cognitive impairment.
  • Alcohol or psychotropic substance abuse.
  • Diagnosis of depression or any severe psychiatric disorder within the 5 years prior to evaluation.
  • Changes in benzodiazepine or antidepressant treatment within the 6 months prior to baseline evaluation.
  • Current treatment with neuroleptics.
  • Epilepsy with active treatment within the last 5 years, or any neurological comorbidity that may cause cognitive impairment or structural brain damage.
  • Unable to read and write in Spanish.
  • Inability to use the study device effectively, as determined during the screening session. This includes, but is not limited to, anatomical or dermatological factors preventing adequate electrode placement, or excessive EEG signal artifacts that prevent reliable detection of sleep oscillations.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Auditory Stimulation Intervention Group

    Participants receive closed-loop auditory stimulation during sleep at home for an initial treatment period of 3 months, followed by a 1-month off-treatment (washout) period. Participants may then enter an optional extension phase consisting of 3 additional months of treatment followed by a second 1-month washout period.

    Device: Closed-Loop Auditory Stimulation

Interventions

  • DeviceClosed-Loop Auditory Stimulation

    The system delivers brief auditory stimuli (pink noise bursts) that are time-locked to the up-phase of endogenous slow oscillations during non-rapid eye movement (NREM) sleep, as detected in real time using electroencephalography (EEG). Stimulation is withheld in approximately half of detected slow oscillations (Sham) to serve as a within-session control condition for the acute effects of stimulation. The other half of the slow oscillations are stimulated at a volume between 30-60 dB (Stim), which is personalized to the patient and adapts during the night to improve response while reducing awakenings. The objective of the stimulation is to enhance slow-wave activity (SWA) during deep sleep through phase-specific entrainment of endogenous slow-wave activity. The intervention is self-administered using a portable system adapted for use in patients with MCI. Participants are instructed to use the device for as many nights as possible throughout the study period.

    Also known as: AudiStim

06

What researchers measure

Primary outcomes

  1. Target Engagement: Sustained Increase in Slow-Wave Activity During N2-N3 Sleep

    Within-subject difference in mean slow-wave activity during N2-N3 sleep between stimulation and sham conditions, computed nightly and aggregated across the intervention period. The sustained effect will be evaluated as the consistency of the stimulation-induced increase in slow-wave activity across nights throughout the intervention period.

    Time frame: Assessed at each intervention night, from baseline through the end of the intervention period (3 months, or up to 7 months for participants entering the extension phase).

Secondary outcomes

  1. Sustained Increase in Spindle Activity During N2-N3 Sleep

    Within-subject difference in spindle activity (spindle occurrence during N2-N3 sleep) between stimulation and sham conditions, computed nightly and aggregated across the intervention period. The sustained effect will be evaluated as the consistency of the stimulation-induced increase in spindle activity across nights throughout the intervention period.

    Time frame: Assessed at each intervention night, from baseline through the end of the intervention period (3 months, or up to 7 months for participants entering the extension phase).

  2. Adherence to the Intervention

    Average number of intervention nights attempted per week. An intervention night is defined as a night during which the participant initiates use of the technology. Adherence will also be summarized as the proportion of participants achieving an average of at least 4 nights per week.

    Time frame: Computed as a summary measure over each participant's full intervention period (3 months, or up to 7 months for participants entering the extension phase).

  3. Usability of the Closed-Loop Auditory Stimulation System

    Percentage of successful sessions among all attempted sessions. A successful session is defined as one in which the participant correctly sets up the device, the system initializes, and usable physiological data are recorded. Sessions may be unsuccessful due to patient-side factors (e.g., electrode placement errors), device-side factors (e.g., technical malfunction), or both.

    Time frame: Computed as a summary measure over each participant's full intervention period (3 months, or up to 7 months for participants entering the extension phase).

  4. Safety and Tolerability

    Incidence, severity, and relatedness of adverse events associated with the intervention, including sleep disturbance, discomfort related to auditory stimulation, and any device-related adverse effects. Safety will be assessed continuously and summarized at interim and final analyses.

    Time frame: Continuously monitored from enrollment through the end of participation, with summary analyses at 3 months and, for participants entering the extension phase, at 7 months.

Other outcomes

  1. Cognitive Performance - Alzheimer's Disease Assessment Scale-Cognitive Subscale, 11-item version (ADAS-Cog 11)

    Change from baseline in global cognitive performance, as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) 11-item version (ADAS-Cog 11). Scores range from 0 to 70, with higher scores indicating poorer cognitive performance.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7).

  2. Functional Ability - Alzheimer's Disease Cooperative Study-Activities of Daily Living scale for Mild Cognitive Impairment (ADCS-ADL-MCI)

    Change from baseline in activities of daily living measured using the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale for Mild Cognitive Impairment (ADCS-ADL-MCI). Scores range from 0 to 69; higher scores indicate better functional ability.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7).

  3. Global Cognition - MoCA

    Change from baseline in global cognitive function, as measured by the Montreal Cognitive Assessment (MoCA). Scores range from 0 to 30, with higher scores indicating better cognitive performance.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7).

  4. Episodic Memory - Rey Auditory Verbal Learning Test (RAVLT) Total Learning Score (Trials 1-5)

    Change from baseline in episodic memory performance, assessed using the Rey Auditory Verbal Learning Test (RAVLT) total learning score (Trials 1-5). Scores range from 0 to 75, with higher scores indicating better episodic memory performance.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7).

  5. Immediate Memory - Wechsler Memory Scale-Fourth Edition (WMS-IV) Logical Memory I

    Change from baseline in immediate memory performance, assessed using the Wechsler Memory Scale-Fourth Edition (WMS-IV) Logical Memory I subtest. Scores range from 0 to 53, with higher scores indicate better immediate memory performance.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7).

  6. Episodic Memory - Wechsler Memory Scale-Fourth Edition (WMS-IV) Logical Memory II

    Change from baseline in episodic memory performance, assessed using the Wechsler Memory Scale-Fourth Edition (WMS-IV) Logical Memory II subtest. Scores range from 0 to 39, with higher scores indicate better episodic memory performance.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7)

  7. Immediate Memory - Wechsler Memory Scale-Fourth Edition (WMS-IV) Verbal Paired Associates I

    Change from baseline in immediate memory performance, assessed using the Wechsler Memory Scale-Fourth Edition (WMS-IV) Verbal Paired Associates I subtest. Scores range from 0 to 40, with higher scores indicate better immediate memory performance.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7)

  8. Episodic Memory - Wechsler Memory Scale-Fourth Edition (WMS-IV) Verbal Paired Associates II

    Change from baseline in episodic memory performance, assessed using the Wechsler Memory Scale-Fourth Edition (WMS-IV) Verbal Paired Associates II subtest. Scores range from 0 to 10, with higher scores indicate better episodic memory performance.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7).

  9. Visual Reproduction - Wechsler Memory Scale-Fourth Edition (WMS-IV) Visual Reproduction I

    Change from baseline in visual memory performance, assessed using the Wechsler Memory Scale-Fourth Edition (WMS-IV) Visual Reproduction I subtest. Scores range from 0 to 43, with higher scores indicating better visual memory performance.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7)

  10. Visual Reproduction - Wechsler Memory Scale-Fourth Edition (WMS-IV) Visual Reproduction II

    Change from baseline in visual memory performance, assessed using the Wechsler Memory Scale-Fourth Edition (WMS-IV) Visual Reproduction II subtest. Scores range from 0 to 43, with higher scores indicating better visual memory performance.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7)

  11. Working Memory - Wechsler Memory Scale-Fourth Edition (WMS-IV) Symbol Span

    Change from baseline in working memory performance, assessed using the Wechsler Memory Scale-Fourth Edition (WMS-IV) Symbol Span subtest. Scores range from 0 to 50, with higher scores indicating better working memory performance.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7)

  12. Working Memory - Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Digit Span

    Change from baseline in working memory, assessed using the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Digit Span subtest. Scores range from 0 to 48, with higher scores indicating better working memory performance

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7).

  13. Working Memory - Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Arithmetic

    Change from baseline in working memory, assessed using the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Arithmetic subtest. Scores range from 0 to 22, with higher scores indicating better working memory performance.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7)

  14. Processing Speed - Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Symbol Search

    Change from baseline in processing speed, assessed using the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Symbol Search subtest. Scores range from 0 to 60, with higher scores indicating better processing speed performance.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7)

  15. Processing Speed - Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Coding

    Change from baseline in processing speed, assessed using the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Coding subtest. Scores range from 0 to 135, with higher scores indicating better processing speed performance.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7).

  16. Anxiety Symptoms - Goldberg Anxiety Scale

    Change from baseline in anxiety symptoms, measured using the Goldberg Anxiety Scale. Scores range from 0 to 9, with higher scores indicating worse anxiety symptoms.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7).

  17. Depressive Symptoms - PHQ-8

    Change from baseline in depressive symptoms, measured using the Patient Health Questionnaire-8 (PHQ-8). Scores range from 0 to 24, with higher scores indicating greater symptom severity.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7).

  18. Patient Self-Reported Experience (Daily)

    Daily subjective cognitive and affective experience assessed using Temporal Experience Tracing (TET). TET is a visual-analog method in which participants retrospectively graph the intensity of an experience along several phenomenological dimensions over time, producing daily compositional profiles of cognitive and emotional states.

    Time frame: Assessed daily on intervention days, from baseline through the end of the intervention period (3 months, or up to 7 months for participants entering the extension phase).

  19. Sleep macrostructure - Sleep duration

    Change from baseline in sleep duration, estimated from EEG recordings. The duration of sleep will be quantified as the Time In Bed (TIB), defined as the full length from the start to the end of the recording; Sleep Period Time (SPT), from the first to the last epoch of sleep; and Total Sleep Time (TST), the cumulative duration of all sleep stages (N1, N2, N3, and REM). Sleep duration will be quantified in minutes. Sleep macrostructure will be measured using the scoring manual of the American Academy of Sleep Medicine (AASM; Iber et al., 2007) as the established standard, obtaining the sleep stage for each 30-sec epoch of the recording.

    Time frame: Assessed at each intervention night, from baseline through the end of the intervention period (3 months, or up to 7 months for participants entering the extension phase).

  20. Sleep macrostructure - Percentage of Time per Sleep Stage

    Change from baseline in the distribution of sleep stages (%): N1, N2, N3, REM, Wake, estimated from EEG recordings. The time spent in each sleep stage will be reported with respect to sleep time, in percentage. Sleep macrostructure will be measured using the scoring manual of the American Academy of Sleep Medicine (AASM; Iber et al., 2007) as the established standard, obtaining the sleep stage for each 30-sec epoch of the recording.

    Time frame: Assessed at each intervention night, from baseline through the end of the intervention period (3 months, or up to 7 months for participants entering the extension phase).

  21. Sleep macrostructure - Efficiency of sleep

    Change from baseline in efficiency of sleep, estimated from EEG recordings. Sleep Efficiency (SE) constitutes the ratio between total sleep time and time in bed, whereas Sleep Maintenance Efficiency (SME) is the ratio between total sleep time and sleep period time, representing the proportion of time spent alseep. Sleep macrostructure will be measured using the scoring manual of the American Academy of Sleep Medicine (AASM; Iber et al., 2007) as the established standard, obtaining the sleep stage for each 30-sec epoch of the recording.

    Time frame: Assessed at each intervention night, from baseline through the end of the intervention period (3 months, or up to 7 months for participants entering the extension phase).

  22. Sleep macrostructure - Wake after sleep onset

    Change from baseline in time spent awake after the onset of sleep, estimated from EEG recordings. Wake After Sleep Onset (WASO) is the accumulated wake time (in minutes) within sleep period time. Sleep macrostructure will be measured using the scoring manual of the American Academy of Sleep Medicine (AASM; Iber et al., 2007) as the established standard, obtaining the sleep stage for each 30-sec epoch of the recording.

    Time frame: Assessed at each intervention night, from baseline through the end of the intervention period (3 months, or up to 7 months for participants entering the extension phase).

  23. Sleep macrostructure - Sleep onset latency

    Change from baseline in sleep onset latency, estimated from EEG recordings. Sleep Onset Latency (SOL) is the time in minutes from the start of the recording to the first epoch of sleep. This metric can also be computed for each individual sleep stage (N1, N2, N3, and REM), measured from the start of the recording to the first occurrence of that stage. Sleep macrostructure will be measured using the scoring manual of the American Academy of Sleep Medicine (AASM; Iber et al., 2007) as the established standard, obtaining the sleep stage for each 30-sec epoch of the recording.

    Time frame: Assessed at each intervention night, from baseline through the end of the intervention period (3 months, or up to 7 months for participants entering the extension phase).

  24. Sleep macrostructure - Sleep fragmentation

    Change from baseline in sleep fragmentation, estimated from EEG recordings. Sleep fragmentation is measured as the number of sleep stage changes (i.e., the number of transitions between diferent stages) througout the night. The number of transitions from any sleep stage (N1, N2, N3, REM) to wake constitute the number of awakenings. Sleep macrostructure will be measured using the scoring manual of the American Academy of Sleep Medicine (AASM; Iber et al., 2007) as the established standard, obtaining the sleep stage for each 30-sec epoch of the recording.

    Time frame: Assessed at each intervention night, from baseline through the end of the intervention period (3 months, or up to 7 months for participants entering the extension phase).

  25. Subjective Sleep Quality - PSQI

    Change from baseline in self-reported sleep quality, measured using the Pittsburgh Sleep Quality Index (PSQI). Global scores range from 0 to 21, with higher scores indicating poorer sleep quality.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7).

  26. Subjective Sleep Quality - ISI

    Change from baseline in insomnia severity, measured using the Insomnia Severity Index (ISI). Scores range from 0 to 28, with higher scores indicating more severe insomnia.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), and end of extension treatment (Month 7).

  27. Daytime Sleepiness

    Daily self-reported daytime sleepiness assessed using the Stanford Sleepiness Scale (SSS). Scores range from 1 to 7, with higher scores indicating greater sleepiness.

    Time frame: Assessed daily on intervention days, from baseline through the end of the intervention period (3 months, or up to 7 months for participants entering the extension phase).

  28. Plasma Amyloid Pathology - Amyloid-Beta 42/40 Ratio

    Change from baseline in plasma amyloid-beta 42/40 ratio, assessed to characterize within-subject temporal dynamics across intervention and washout periods. Higher values indicate a higher amyloid-beta 42/40 ratio.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), end of first washout (Month 4), end of extension treatment (Month 7), and end of second washout (Month 8).

  29. Plasma Phosphorylated Tau 217 (p-tau217)

    Percent change from baseline in plasma phosphorylated tau 217 (p-tau217). Values will be reported as percent change (%), with negative values representing decreases and positive values representing increases relative to baseline.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), end of first washout (Month 4), end of extension treatment (Month 7), and end of second washout (Month 8)

  30. Plasma Neurodegeneration Biomarker - Glial Fibrillary Acidic Protein (GFAP)

    Percent change from baseline in plasma glial fibrillary acidic protein (GFAP), assessed to characterize within-subject temporal dynamics across intervention and washout periods. Values will be reported as percent change (%); negative values indicate a decrease and positive values indicate an increase in circulating GFAP levels relative to baseline.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), end of first washout (Month 4), end of extension treatment (Month 7), and end of second washout (Month 8).

  31. Plasma Neurodegeneration Biomarker - Neurofilament Light Chain (NfL)

    Percent change from baseline in plasma neurofilament light chain (NfL), assessed to characterize within-subject temporal dynamics across intervention and washout periods. Values will be reported as percent change (%); negative values indicate a decrease and positive values indicate an increase in circulating NfL levels relative to baseline.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), end of first washout (Month 4), end of extension treatment (Month 7), and end of second washout (Month 8).

  32. Plasma Inflammatory Biomarker - Interleukin-6 (IL-6)

    Percent change from baseline in plasma interleukin-6 (IL-6), assessed to characterize within-subject temporal dynamics across intervention and washout periods. Values will be reported as percent change (%); negative values indicate a decrease and positive values indicate an increase in circulating IL-6 levels relative to baseline.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), end of first washout (Month 4), end of extension treatment (Month 7), and end of second washout (Month 8)

  33. Plasma Inflammatory Biomarker - Interleukin-10 (IL-10)

    Percent change from baseline in plasma interleukin-10 (IL-10), assessed to characterize within-subject temporal dynamics across intervention and washout periods. Values will be reported as percent change (%); negative values indicate a decrease and positive values indicate an increase in circulating IL-10 levels relative to baseline.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), end of first washout (Month 4), end of extension treatment (Month 7), and end of second washout (Month 8).

  34. Plasma Inflammatory Biomarker - Tumor Necrosis Factor Alpha (TNF-alpha)

    Percent change from baseline in plasma tumor necrosis factor alpha (TNF-alpha), assessed to characterize within-subject temporal dynamics across intervention and washout periods. Values will be reported as percent change (%); negative values indicate a decrease and positive values indicate an increase in circulating TNF-alpha levels relative to baseline.

    Time frame: Assessments at baseline (Month 0), end of initial treatment (Month 3), end of first washout (Month 4), end of extension treatment (Month 7), and end of second washout (Month 8).]

07

Study locations

1 site
  • Bit&Brain Technologies SL
    Zaragoza, Zaragoza 50006, Spain
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Sep 2026, 14 months.

Of 69 industry-sponsored interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's 14 months is close to that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Nov 2026 → Sep 2026 and completion Dec 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 29, 2026
StartActual
Jul 1, 2025
Primary completionActual
Sep 30, 2026was Nov 2026
CompletionActual
Oct 30, 2026was Dec 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Nov 13, 2026
Primary completion
Nov 30, 2026→Sep 30, 2026 (actual)
Nov 13, 2026
Study completion
Dec 30, 2026→Oct 30, 2026 (actual)
Nov 13, 2026
Enrollment
30 (estimated)→25 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Enrolling by invitation→Completed
    Primary completion Nov 30, 2026→Sep 30, 2026 (now actual)
    Study completion Dec 30, 2026→Oct 30, 2026 (now actual)
    Enrollment 30 (estimated)→25 (actual)
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07672977
Lead sponsor
Bitbrain
Collaborators
Aragon Institute for Health Research (IIS Aragón), Hospital Miguel Servet de Zaragoza, Hospital Clínico Zaragoza, Hospital Universitario Royo Villanova, Universidad de Zaragoza
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Jul 1, 2025
Primary completion
Sep 30, 2026
Completion
Oct 30, 2026
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion